OUR LEADERSHIP TEAM, BOARD MEMBERS AND ADVISORS ARE CANCER IMMUNOLOGISTS, DRUG DEVELOPERS AND COMPANY BUILDERS WITH EXTENSIVE INDUSTRY EXPERIENCE. AS A TEAM, WE ARE LEVERAGING OUR DIVERSE EXPERTISE AND PASSION FOR INNOVATION TO BUILD A SUSTAINABLE COMPANY AND FIND CURES FOR CANCER PATIENTS.


ADVISORS

Mitchell (Mitch) Finer, PhD | TCR2 Chairman of the Advisory Board
Member of TCR2 Board of Directors
Managing Director, MPM Capital, Cambridge, MA
Chief Executive Officer and Chief Scientific Officer, Oncorus, Cambridge, MA

Stephan Grupp, MD and PhD
Yetta Deitch Novotny Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania
Chief of the Section of Cellular Therapy and Transplant, Children’s Hospital of Philadelphia, PA

Marcela Maus, MD and PhD
Assistant Professor of Medicine, Harvard Medical School
Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, Boston, MA

Wolfgang Schamel, PhD
Professor and Chairman, Institute of Biology III (Molecular Immunology) and Centre for
Biological Signaling Studies (BIOSS), University of Freiburg, Germany

Kai Wucherpfennig, MD and PhD
Professor and Chairman, Department of Cancer Immunology and
Virology Director of Center for Cancer Immunotherapy Research, Boston, MA